TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19037029
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg every 4-6 hours until 37 weeks of gestation)
Study: 12505741
Drug: Respondents who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Respondents who indicated they were likely to administer CPR
Study: 14763548
Drug: Graftjacket tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graftjacket tissue matrix (single administration)
Study: 21703900
Drug: Ibandronate 150
Normalized name: ibandronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 150 mg monthly with CTX feedback (Group B)
Study: 26661906
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg/Metformin
Study: 26661906
Drug: Canagliflozin 300
Normalized name: canagliflozin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 300 mg/Metformin
Study: 21350803
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy for advanced gastric cancer
Study: 14633812
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (100 mg/day)
Study: 11776303
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin and low dose aspirin
Study: 3502238
Drug: Complex herb
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex herb preparation PADMA
Study: 17409842
Drug: Gemcitabine-carboplatin-paclitaxel combination
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine-carboplatin-paclitaxel combination chemotherapy
Study: 29807962
Drug: Control sites
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control sites (no hyaluronic acid gel)
Study: 31353997
Drug: Diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac gel (1.16%)
Study: 19378232
Drug: Rapid intravenous
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid intravenous volume expansion (group A)
Study: 17530112
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch and bupropion
Study: 29501366
Drug: Nedaplatin 100
Normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedaplatin 100 mg/m2 on days 1, 22, and 43 for three cycles concurrently with intensity-modulated radiotherapy
Study: 7911639
Drug: Acetazolamide administration
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide administration
Study: 23107591
Drug: Afluria inactivated
Normalized name: Afluria 2024-2025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afluria inactivated vaccine
Study: 23107591
Drug: Live influenza
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live influenza vaccine (Flumist)
Study: 23107591
Drug: Inactivated vaccines
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated vaccines (general)
Study: 18568788
Drug: Estrogen-progestin treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-progestin treatment (EPT) in postmenopausal women
Study: 8565024
Drug: Nabumetone 1500
Normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nabumetone 1500 mg once daily
Study: 15353899
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy alone (control group)
Study: 2117857
Drug: Allopurinol 900
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 900 mg/day for 60 days
Study: 25476069
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (3 mg, six 2-monthly oral doses over 1 year)
Study: 10792116
Drug: Ketoprofen 25
Normalized name: ketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 25 mg t.d.s.
Study: 16279825
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg naproxen sodium
Study: 9885387
Drug: levodopa benzeraside
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: levodopa benzeraside 2 mg/kg 3 times per day for 1 week
Study: 9081359
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.8 mg/kg/day)
Study: 7557064
Drug: Levocabastine ophthalmic
Normalized name: levocabastine ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine ophthalmic solution (0.5 mgrs/ml), one drop every 12 hours for seven days
Study: 27168455
Drug: Control product
Normalized name: Patch test control product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control product (100 g, twice daily for 3 months)
Study: 31099474
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol 0.5% q12h
Study: 7005872
Drug: nicergoline 30
Normalized name: nicergoline 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nicergoline 30 mg/day divided into 6 doses
Study: 30760332
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy (NPWT) with silver-impregnated dressings via RENASYS TOUCH™ vacuum pump
Study: 23023384
Drug: Betamethasone treatment
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone treatment
Study: 29893790
Drug: Palbociclib in
Normalized name: Product containing palbociclib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib in combination with endocrine therapy (ET)
Study: 26607829
Drug: 25-G needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-G needle
Study: 26607829
Drug: 22-G needle
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 22-G needle
Study: 27618825
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg every 2 weeks (Q2W)
Study: 10591283
Drug: Intensive behavioral
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive behavioral treatment (parent, school, and child components)
Study: 24144761
Drug: Oral NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral NSAIDs
Study: 25081826
Drug: PAS 400
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAS 400 (400 mg PS & 400 mg PA per day)
Study: 11337927
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of mt‐PA (monteplase) 15,000 IU/kg
Study: 28241037
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bisacodyl plus 2 L PEG‐ELP (group B)
Study: 26096139
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (1000 mg + 5 mg prednisone twice daily) + high-fat meal
Study: 24128821
Drug: Fentanyl pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl pectin nasal spray (FPNS) at 100-800 μg titrated doses
Study: 7861719
Drug: Cyclosporin treatment
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin treatment
Study: 28467333
Drug: Topical phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical phenytoin (5 mg/L in 0.9% NaCl solution), applied for 3 hours every 12 hours
Study: 24622413
Drug: rhPTH(1-84) 50
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhPTH(1-84) 50 μg per day
Study: 26771550
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine
Study: 31182440
Drug: Active pulsed
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pulsed low-frequency magnetic field (PLFMF) therapy
Study: 24074484
Drug: Flexible dose
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dose aripiprazole (3-15 mg/day)
Study: 22110105
Drug: Potassium excretion
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium excretion 1.5-1.99 g/day
Study: 17192690
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate spray
Study: 30012107
Drug: Serum free
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum free light chain level >800 mg/L
Study: 23747768
Drug: qili qiangxin
Normalized name: Qilib
Approvals — FDA: no, EMA: no, PMDA: no
Description: qili qiangxin capsules
Study: 26748844
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (ACEi)
Study: 2667598
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of CGP 38 560 A at doses of 50, 100, and 200 mg
Study: 12938828
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin ointment applied twice per day for 7 days
Study: 9003923
Drug: Gadodiamide injection
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadodiamide injection
Study: 21183500
Drug: N-terminal pro
Normalized name: N-terminal pro-B-type natriuretic peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-terminal pro B-type natriuretic peptide (NT-proBNP) ≥400 pg/mL
Study: 2575369
Drug: Cicletanine 50
Normalized name: cicletanine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 50 mg/day
Study: 17373638
Drug: Vildagliptin 100
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 100 mg
Study: 18932258
Drug: ABT-510 20
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-510 20 mg QD
Study: 29364743
Drug: I-Gel airway
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-Gel airway (IGA)
Study: 18030180
Drug: Proportion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proportion of treatment prescribed
Study: 31580094
Drug: Nietos Activos
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nietos Activos y Saludables intervention (4 weekly sessions)
Study: 1620417
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg at 22 hours the night before surgery
Study: 2949417
Drug: Zoladex 3.6
Normalized name: Zoladex 3.6mg Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex 3.6 mg once-monthly depot
Study: 19352048
Drug: Mitiglinide 5
Normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mitiglinide 5 mg
Study: 16285312
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with methylaminooxopentanoate (Metvix) and a broad band light source (PhotoDyn 501)
Study: 6340806
Drug: Propranolol 120
Normalized name: propranolol 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 120 mg
Study: 27164293
Drug: Low-dose exercise
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exercise (4 kcal/kg of weight/week)
Study: 26118427
Drug: Alisporivir (ALV)
Normalized name: ALV-001
DrugBank: Alisporivir (DB12139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisporivir (ALV) 600 mg QD and pegylated interferon (Peg-IFN)
Study: 16633141
Drug: Itraconazole pretreatment
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole pretreatment (200 mg/d for 10 days)
Study: 18005381
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA with remifentanil
Study: 23890679
Drug: Augmentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation of labour
Study: 9459373
Drug: Onion consumption
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion consumption (220 g onions/d providing 114 mg quercetin/d)
Study: 7675948
Drug: alprazolam 0.5
Normalized name: alprazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: alprazolam 0.5 mg
Study: 15048331
Drug: Ilizarov technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilizarov technique in combination with minimally invasive internal fixation (group I)
Study: 19927544
Drug: Captisol-enabled budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Captisol-enabled budesonide solution (CBIS), 60 microg twice daily
Study: 18242276
Drug: Higher intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher intensity statin dosing (>= 40 mg atorvastatin)
Study: 9058850
Drug: Electrocardiographic Monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrocardiographic Monitoring guided therapy
Study: 17010685
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate (2 g/day)
Study: 7801588
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of metromidasole with dimethysulfoxide
Study: 30156193
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) - single dose immediately after surgery (0.3 W, 40 s, 4 J/cm2)
Study: 12963608
Drug: Verteporfin therapy
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin therapy
Study: 27555193
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block (15‐20 mL 0.5% ropivacaine, maximum 3 mg/kg)
Study: 10997428
Drug: Salbutamol 200
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 200 microg inhalation
Study: 30360984
Drug: HMB-FA 3
Normalized name: folic acid 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB-FA 3 × 1 g/day
Study: 16352931
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg/day
Study: 11032209
Drug: Fluid administered
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid administered during the first 48 hours (mean=5824 mL)
Study: 8773160
Drug: Aspirin 975
Normalized name: aspirin 975 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 975 mg qid for 4 days
Study: 8773160
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg qid for 4 days
Study: 30165520
Drug: Higher LT4
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Higher LT4 dose
Study: 30165520
Drug: Adjusting LT4
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjusting LT4 doses
Study: 16644612
Drug: Molsidomine twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molsidomine twice-daily 8 mg (M8)
Study: 23332456
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50, or 70 mg/day
Study: 26794472
Drug: Narrow-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-spectrum antibiotics
Study: 17486027
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) in PDE study
Study: 17486027
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) in SS study
Study: 30417648
Drug: Ibuprofen immediate-release
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen immediate-release (IR) tablet
Study: 1101843
Drug: Amitriptyline hydrochloride,
Normalized name: Amitriptyline Hydrochloride, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline hydrochloride, 125 mg/day
Study: 14999109
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (500 to 3000 mg per day)
Study: 22012943
Drug: Treatment fidelity
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment fidelity strategies
Study: 12783595
Drug: Natalizumab 6
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab 6 mg/kg every 28 days
Study: 23656810
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) + drug group
Study: 15849531
Drug: Intensive monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intensive monthly counseling sessions about condom use (8 sessions)
Study: 12444179
Drug: Control injection
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control injection
Study: 11121916
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg
Study: 9689421
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (ISMN) 60 mg/d
Study: 22248761
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia with bupivacaine and epidural morphine
Study: 20658749
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy interruption
Study: 15297
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg t.i.d.
Study: 17057389
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no mistletoe therapy)
Study: 7726440
Drug: Midazolam infusion
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam infusion (0.13 +/- 0.04 mg.kg‐1.h‐1)
Study: 18340278
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50 mug/day) plus medroxyprogesterone acetate (5 mg/day)
Study: 25579357
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% eye drops twice daily for 4 weeks
Study: 19996339
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily for 28 days
Study: 7620470
Drug: Ego-oriented individual
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ego-oriented individual therapy (EOIT)
Study: 1137332
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose solution infusion (glucose group)
Study: 7789055
Drug: Natural estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Natural estradiol (0.05 mg/day) and medroxyprogesteron acetate (10 mg/day) for 6 months
Study: 7675971
Drug: SSRI-RIMA combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI-RIMA combination treatment (fluvoxamine and moclobemide)
Study: 8556398
Drug: Zalcitabine (ddC)
Normalized name: ZALCITABINE (ddC) 0.75MG TAB
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zalcitabine (ddC) 2.25 mg daily
Study: 11134261
Drug: Profiled treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profiled treatments
Study: 9617983
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (300 mg every 12 hours) with naproxen sodium
Study: 15704481
Drug: Phezam treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phezam treatment for 2 months in routine practice
Study: 26210120
Drug: Topical fluoride
Normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoride applications (IPFA)
Study: 2014931
Drug: Bambuterol 5
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol 5 mg